RELINIFY
Live / Applied — Fifth extension granted (statement of use) (as of 28 Jan 2026)
What this means for you
Not registered yet, but its 13 Sept 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97589986
- Mark type
- Stylized text
- Filed
- 13 Sept 2022
- Published for opposition
- 29 Aug 2023
- Attorney of record
- Karl M. Zielaznicki, Esq.
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals for use in the treatment of cancer and blood diseases and disorders
- Class 042 — Scientific and technological services: Medical research and medical research information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders
- Class 044 — Medical, beauty and agricultural services: Medical information services in the fields of pharmaceuticals, oncology, and blood diseases and disorders
Owner
- TAKEDA PHARMACEUTICALS U.S.A., INC., CAMBRIDGE, MA, US
- Protagonist Therapeutics, Inc., Newark, CA, US
- Protagonist Therapeutics, Inc., Newark, CA, US
Prosecution history
- 28 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 28 Jan 2026 — SOU EXTENSION 5 GRANTED
- 28 Jan 2026 — SOU EXTENSION 5 FILED
- 27 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Sept 2025 — SOU EXTENSION 4 GRANTED
- 03 Sept 2025 — SOU EXTENSION 4 FILED
- 03 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Feb 2025 — SOU EXTENSION 3 GRANTED
- 07 Feb 2025 — SOU EXTENSION 3 FILED
- 07 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Nov 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2024 — SOU EXTENSION 2 GRANTED
- 18 Oct 2024 — SOU EXTENSION 2 FILED